Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokineinduced killer cell therapy in cancer patients

By Cui Yu   Yang Xuejing   Zhu Wei   Li Jiali   Wu Xiaojing   Pang Yan  

Oncology Letters, Vol. 6, Iss. 2, 2013-08 ,pp. : 537-541

Spandidos Publications

Access to resources Recommend Favorite

Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses

By              

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 529-534

Spandidos Publications

Access to resources Recommend Favorite

Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells

By Matsuda Kenji   Tsunoda Takuya   Tanaka Hajime   Umano Yasukazu   Tanimura Hiroshi   Nukaya Ikuei   Takesako Kazutoh   Yamaue Hiroki  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 609-616

Springer Publishing Company

Access to resources Recommend Favorite

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

By Svane Inge   Pedersen Anders   Johnsen Hans   Nielsen Dorte   Kamby Claus   Gaarsdal Eva   Nikolajsen Kirsten   Buus Søren   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite

SLC gene-modified dendritic cells mediate T cell-dependent anti-gastric cancer immune responses in vitro

By              

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 595-604

Spandidos Publications

Access to resources Recommend Favorite